Applied BioCode - Asset Resilience Ratio
Applied BioCode (6598) has an Asset Resilience Ratio of 9.75% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2024)
This chart shows how Applied BioCode's Asset Resilience Ratio has changed over time. Check 6598 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Applied BioCode's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Applied BioCode stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$100.55 Million | 9.75% |
| Total Liquid Assets | NT$100.55 Million | 9.75% |
Asset Resilience Insights
- Limited Liquidity: Applied BioCode maintains only 9.75% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Applied BioCode Industry Peers by Asset Resilience Ratio
Compare Applied BioCode's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Bio-Rad Laboratories Inc
NYSE:BIO |
Medical Devices | 10.80% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
Tellgen Corp
SHE:300642 |
Medical Devices | 9.96% |
|
Affluent Medical SAS
PA:AFME |
Medical Devices | 0.03% |
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Imricor Medical Systems Inc
AU:IMR |
Medical Devices | 46.50% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
Annual Asset Resilience Ratio for Applied BioCode (2012–2024)
The table below shows the annual Asset Resilience Ratio data for Applied BioCode.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 20.70% | NT$251.53 Million ≈ $7.92 Million |
NT$1.21 Billion ≈ $38.28 Million |
+1.41pp |
| 2023-12-31 | 19.29% | NT$191.62 Million ≈ $6.04 Million |
NT$993.21 Million ≈ $31.29 Million |
+2.42pp |
| 2019-12-31 | 16.87% | NT$121.33 Million ≈ $3.82 Million |
NT$719.01 Million ≈ $22.65 Million |
+16.57pp |
| 2018-12-31 | 0.30% | NT$1.54 Million ≈ $48.61K |
NT$514.07 Million ≈ $16.20 Million |
+0.04pp |
| 2017-12-31 | 0.26% | NT$890.00K ≈ $28.04K |
NT$336.83 Million ≈ $10.61 Million |
-69.42pp |
| 2016-12-31 | 69.69% | NT$333.63 Million ≈ $10.51 Million |
NT$478.77 Million ≈ $15.08 Million |
+50.99pp |
| 2015-12-31 | 18.69% | NT$58.14 Million ≈ $1.83 Million |
NT$310.99 Million ≈ $9.80 Million |
+2.99pp |
| 2014-12-31 | 15.71% | NT$55.70 Million ≈ $1.75 Million |
NT$354.66 Million ≈ $11.17 Million |
+4.16pp |
| 2013-12-31 | 11.55% | NT$22.47 Million ≈ $707.93K |
NT$194.56 Million ≈ $6.13 Million |
+3.27pp |
| 2012-12-31 | 8.28% | NT$21.79 Million ≈ $686.35K |
NT$262.99 Million ≈ $8.29 Million |
-- |
About Applied BioCode
Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California. Its products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the detection steps, PCR amplification, and hybridization and target capture; and the BioCode 2500 analyzer, a system that reads each barcode and quantifies the BMB target us… Read more